No evidence for an impact of the RCT results on uptake by ECPs in the US, so not a lot of joy there.
A couple of things that took the eye though:
- Menicon bloom seems to out-selling Naturalvue to some extent, suggesting the Menicon release in Europe is gaining traction, influencing the gross margin. The margin for VTI on a sale of menicon bloom day will be considerably lower than a sale in the US to an ECP via a distributor.
- A strong statement on the relative efficacy of Naturalvue vs Misight based on further statistical analysis of the 1-year RCT result by the independent CRO. This needs to get into a peer-reviewed paper asap so ECPs take notice.
More evidence of strong sales now would have been welcome, but the relative performance is where the long-term return will come from IMO.
- Forums
- ASX - By Stock
- Ann: Business Activity Statement & Appendix 4C - Mar-2024 Qtr
No evidence for an impact of the RCT results on uptake by ECPs...
Featured News
Add VTI (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.257M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
11.5¢ | 1429 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 0.100 |
1 | 10309 | 0.097 |
2 | 20047 | 0.096 |
5 | 83159 | 0.095 |
1 | 10000 | 0.091 |
Price($) | Vol. | No. |
---|---|---|
0.115 | 1429 | 1 |
0.130 | 15000 | 1 |
0.140 | 13345 | 1 |
0.160 | 11616 | 1 |
0.165 | 6000 | 1 |
Last trade - 16.12pm 03/05/2024 (20 minute delay) ? |
Featured News
VTI (ASX) Chart |
Day chart unavailable